What's in PT Otsuka Indonesia's pipeline?

PT Otsuka Indonesia has 1 drugs in our index: 0 marketed, 0 filed, 1 in Phase 3, 0 in Phase 2, 0 in Phase 1.

Which companies overlap with PT Otsuka Indonesia's portfolio?

Top competitors by shared drug class: Amphastar Pharmaceuticals, Inc., AstraZeneca, GlaxoSmithKline, Teva Branded Pharmaceutical Products R&D, Inc..

How do I subscribe to ongoing alerts?

Subscribe to /feed/company/pt-otsuka-indonesia.xml in any RSS reader. Every regulatory action and pipeline update lands in your feed.

Last reviewed 2026-05-16 · How we verify

PT Otsuka Indonesia — Portfolio Competitive Intelligence Brief

PT Otsuka Indonesia pipeline: 0 marketed, 0 filed, 1 Phase 3, 0 Phase 2. Recent regulatory actions, upcoming PDUFA, patent timeline, top competitor overlap.

0 marketed 0 filed 1 Phase 3 0 Phase 2 0 Phase 1 Live · 30-min refresh

Portfolio leaders (marketed + Phase 3 / filed)

Drug	Generic	Phase	Class	Target	Area	First approval
Procaterol, Salbultamol	Procaterol, Salbultamol	phase 3	Beta-2 adrenergic receptor agonist	Beta-2 adrenergic receptor	Respiratory

Therapeutic area mix

Respiratory · 1

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this portfolio.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this portfolio.

Patent timeline (forward window)

No upcoming patent expiries for this portfolio.

Competitive overlap (companies sharing drug classes)

Amphastar Pharmaceuticals, Inc. · 1 shared drug class
AstraZeneca · 1 shared drug class
GlaxoSmithKline · 1 shared drug class
Teva Branded Pharmaceutical Products R&D, Inc. · 1 shared drug class

Subscribe to ongoing alerts

Every new pipeline event for PT Otsuka Indonesia:

Cite this brief

Drug Landscape (2026). PT Otsuka Indonesia — Portfolio Competitive Intelligence Brief. https://druglandscape.com/ci/company/pt-otsuka-indonesia. Accessed 2026-05-16.